AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
It is shown that a blood-based circular RNA signature can accurately detect Alzheimer’s disease as well as, or better than, current biomarkers and even predict who will develop symptoms before they appear.
BBMs play a crucial role in combating Alzheimer’s disease and should be prioritized. To embed them in routine primary care, it is essential for governments and health organizations to finance evaluations in varied demographics, establish coverage policies, and integrate BBMs into existing workflows. Their accuracy, comparable to traditional invasive methods, enables early detection of AD, allowing for lifestyle adjustments and therapies that may hinder or delay disease progression. For patients, this means gaining a sense of control, meeting their needs, and moving forward without the burden of an uncertain diagnosis. This is not merely a transient trend; embracing BBMs could fundamentally alter the perception of aging in a future where Alzheimer’s disease diminishes in prominence.
Blood‐based biomarkers are essential for early detection, monitoring, and therapeutic development in Alzheimer's disease (AD) and related dementia (ADRD), but current assays lack brain cell specificity and sensitivity to low‐abundant proteins.
This work aimed to evaluate the association between U‐p53AZ with established cerebrospinal fluid (CSF) and neuroimaging measures, and to determine its diagnostic performance in distinguishing cognitively normal individuals from those with mild cognitive impairment (MCI).
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.